Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19

Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19

Blog Article

BackgroundPTX3 is an important mediator of inflammation and innate immunity.We aimed at assessing its prognostic value in a large cohort of patients hospitalized with COVID-19.MethodsLevels of PTX3 were measured in 152 patients hospitalized with COVID-19 at San Gerardo Hospital (Monza, Italy) since March 2020.

Cox regression was used to identify predictors of time from admission to in-hospital death or mechanical ventilation.Crude incidences of death were compared between patients with PTX3 levels higher or lower than the best Rug Wash cut-off estimated with the Maximally Selected Rank Statistics Method.ResultsUpon admission, 22% of the patients required no oxygen, 46% low-flow oxygen, 30% high-flow nasal cannula or CPAP-helmet and 3% MV.

Median level of PTX3 was 21.7 (IQR: 13.5-58.

23) ng/ml.In-hospital mortality was 25% (38 deaths); 13 patients (8.6%) underwent MV.

PTX3 was associated with risk of death (per 10 ng/ml, HR 1.08; 95%CI 1.04-1.

11; P<0.001) and death/MV (HR 1.04; 95%CI 1.

01-1.07; P=0.011), independently of other predictors of in-hospital mortality, including age, Charlson Comorbidity Index, D-dimer and C-reactive protein (CRP).

Patients kids purse with PTX3 levels above the optimal cut-off of 39.32 ng/ml had significantly higher mortality than the others (55% vs 8%, P<0.001).

Higher PTX3 plasma levels were found in 14 patients with subsequent thrombotic complications (median [IQR]: 51.4 [24.6-94.

4] versus 21 [13.4-55.2]; P=0.

049).ConclusionsHigh PTX3 levels in patients hospitalized with COVID-19 are associated with a worse outcome.The evaluation of this marker could be useful in prognostic stratification and identification of patients who could benefit from immunomodulant therapy.